Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Wins Rights To Enanta’s Preclinical HCV Protease Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

Collaboration moves Abbott into an increasingly competitive area of research.

You may also be interested in...



Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta

The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.

J&J/Vertex HCV Protease Inhibitor Results Tempered By Higher Adverse Events

Vertex says Phase III trials still on track for 2007.

J&J/Vertex HCV Protease Inhibitor Results Tempered By Higher Adverse Events

Vertex says Phase III trials still on track for 2007.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel